PDCD1 and pachyonychia congenita: Patients in the immune‐activated subgroup of the AHMU‐PC cohort seemed to benefit more from anti‐PD‐1/PD‐L1 immunotherapy than patients in the non‐immune‐activated class (Bonferroni‐corrected P = 0.0399, Fig. 4C).